Tag: biotech
-

Economist Iyer’s Annual Report Tracks Bellwater’s Shrinking Skills Gap
Economist Samuel Iyer’s annual skills-gap report finds the region’s shortfall of qualified technical workers has narrowed to about 1,200 positions, down from a peak of 2,100 three years ago, though he warns the pace remains too slow.
-

Ridgeline Therapeutics Raises Its Own Funding Round Amid Talent Competition With Kestrel
Ridgeline Therapeutics has closed a $38 million funding round it says is aimed at competing with rival Kestrel Biologics for Bellwater’s limited pool of biotech talent.
-

City Weighs Height Limits for Next Wave of Foundry Row Towers
A proposal to cap new Foundry Row towers at 12 stories has split biotech employers seeking room to grow from tenant advocates who say unchecked height will accelerate displacement, with a council vote expected in coming weeks.
-

New Foundry Row Parking Garage Tied to Biotech Campus Expansion
The city and Kestrel Biologics will split the cost of a 600-space Foundry Row parking garage tied to the biotech firm’s hiring surge, a deal some residents say undercuts the neighborhood’s new transit line.
-

New Kincaid Spinout Closes Seed Funding Round
Halcyon Biotherapeutics, Kincaid University’s newest biotech spinout, has closed an $8 million seed funding round to fund its first 18 months of preclinical research.
-

Report Finds Foundry Row Biotech Cluster Has Doubled Jobs in Five Years
A new city-commissioned report finds Foundry Row’s biotech cluster has roughly doubled its workforce in five years, though hiring growth has slowed amid a persistent shortage of trained technicians.
-

Bellwater State Breaks Ground on New Biomanufacturing Lab
Bellwater State broke ground on a $42 million biomanufacturing lab funded partly by Kestrel Biologics, aiming to close a persistent skills gap in the region’s growing biotech sector.
-

Kincaid’s Technology-Transfer Office Announces a Second Biotech Spinout
Kincaid University’s technology-transfer office has announced Halcyon Biotherapeutics, its second biotech spinout, built around a faculty lab’s autoimmune-disease research.